Evaluation of resistin, prolactin, and aromatase in women with breast cancer

Abstract

Cancer is a group of diseases characterized by uncontrolled cell division leading to growth of abnormal tissue, it is a common term for tumors that affect the body's organs, which are the two types of benign tumors and malignant tumors (which are known as carcinoid tumors). A distinction is made between them by examining the tissue (taking a sample). Breast cancer (BC) is formed due to a change in the functioning and growth of cells that make up breast tissue without the ability to control it, which turns them into cancer cells with the ability of these cells to spread. The aims of the study were to evaluate serum levels of resistin (RST), prolactin (PRL), aromatase (ARO), in women with breast cancer and compared with apparently healthy women (control). This study is a cross-sectional, hospital-based study, the protocol of this study was approved by the scientific committee of Tikrit University College of Medicine, and the agreement of the attendance to Kirkuk Oncology Center, Kirkuk general hospital to collect the sample from the patients was approved by the Kirkuk Health Directorate. This study was carried out at the Oncology Center in Kirkuk City-Iraq from the beginning of December 2022 to the end of May 2023. The subject enrolled in the study were divided into (44) breast cancer women and (42) apparently healthy women as control In Kirkuk city. The highest percentage of age for women with BC equal to (34.1%) in the age group (50-59) years, with mean age, was 48.7 years and the statistical tests data obtained showed: highest significant elevation of RST, PRL, and ARO level in women with BC were 6.8±1.8 ng/ml, 58.7±8.4 ng/ml, and 1.5±0.4 pg/ml as compared to control group 4.4±0.5 ng/ml, 24.4±7.2 ng/ml, and 0.4±0.2 pg/ml respectively at (p<0.001). The present study conclude that levels of resistin, prolactin, and aromatase dismutase were significantly higher in women with breast cancer compared to the control.